子宫内膜异位症恶变

doi:10.6040/j.issn.1671-7554.0.2019.494

摘要/Abstract

摘要： 子宫内膜异位症是子宫内膜间质及腺体在子宫腔以外部位浸润生长导致的一类疾病,见于育龄期女性。在临床实践中发现,子宫内膜异位症虽然是个良性疾病,但其仍有恶变的风险。本文从子宫内膜异位症与卵巢癌发病关系、其恶变高危因素、恶变的相关分子机制及如何预防子宫内膜异位症恶变的发生进行阐述与探讨。

关键词: 子宫内膜异位症恶变, 子宫内膜异位症, 卵巢癌, 抑癌基因, 氧化应激反应

Abstract: Endometriosis, characterized by the presence of extra-uterine endometrium, is a common gynecologic disorder in reproductive-age women. In clinical practice, although endometriosis is recognized as a benign disease, it still has the risk of malignant change. This review mainly presents the relationship between endometriosis and ovarian tumors, and probes into the risk factors, molecular mechanism and prevention of malignant transformation.

Key words: Malignant transformation, Endometriosis, Ovarian tumor, Tumor suppressor genes, Oxidative stress

中图分类号:

R737.3

刘崇东,娄彤,董靖. 子宫内膜异位症恶变[J]. 山东大学学报 (医学版), 2019, 57(6): 27-32.

LIU Chongdong, LOU Tong, DONG Jing. Malignant transformation of endometriosis[J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 27-32.

参考文献

[1] ViganòP, Parazzini F, Somigliana E, et al. Endometriosis: epidemiology and aetiological factors [J]. Best Pract Res Clin Obstet Gynaecol, 2004, 18(2):177-200.
[2] Hickey M, Ballard K, Farquhar C. Endometriosis [J]. BMJ(Clinical research ed.), 2014, 348: g1752. doi: 10.1136/bmj.g1752.
[3] Halme J, Hammond MG, Hulka JF, et al. Retrograde menstruation in healthy women and in patients with endometriosis [J]. Obstet Gynecol, 1984, 64(2): 151-154.
[4] Abrao MS, Podgaec S, Dias JA Jr., et al. Deeply infiltrating endometriosis affecting the rectum and lymph nodes [J]. Fertil Steri, 2006, 86(3): 543-547.
[5] Guo SW, Zilberberg MD, Hummelshoj L. Endometriosis and Ovarian cancer [J]. Lancet Oncol, 2012, 13(5): e189-190. doi: 10.1016/S1470-2045(12)70199-7.
[6] Jiang X, Morland SJ, Hitchcock A, et al. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage[J]. Cancer Res, 1998, 58(8): 1707-1712.
[7] Somigliana E, Vigano P, Parazzini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence[J]. Gynecol Oncol, 2006, 101(2): 331-341.
[8] Wang S, Qiu L, Lang JH, et al. Clinical analysis of ovarian epithelial carcinoma with coexisting pelvic endometriosis[J]. Am J Obstet Gynecol, 2013, 208(5): 413. doi: 10.1016/j.ajog.2012.12.004.
[9] Lee WL, Chang WH, Wang KC, et al. The risk of epithelial ovarian cancer of women with endometriosis may be varied greatly if diagnostic criteria are different: a nationwide population-based cohort study [J].Medicine(Baltimore), 2015, 94(39):e1633.
[10] Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies [J]. Lancet Oncol, 2012, 13(4):385-394.
[11] Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility[J]. Fertil Steril, 2004, 82(2): 405-414.
[12] Wang KC, Chang WH, Lee WL, et al. An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis[J]. BMC Cancer, 2014, 14: 831. doi: 10.1186/1471-2407-14-831.
[13] Kobayashi H, Sumimoto K, Kitanaka T, et al. Ovarian endometrioma—risks factors of ovarian cancer development [J]. Eur J Obstet Gynecol Reprod Biol, 2008, 138(2): 187-193.
[14] Thomsen LH, Schnack TH, Buchardi K, et al. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review[J]. Acta Obstet Gynecol Scand, 2017, 96(6):761-778.
[15] Kadan Y, Fiascone S, McCourt C, et al. Predictive factors for the presence of malignant transformation of pelvic endometriosis[J]. Eur J Obstet Gynecol Reprod Biol, 2015, 185:23-27. doi: 10.1016/j.ejogrb.2014.11.029.
[16] Sekizawa A, Amemiya S, Otsuka J, et al. Malignant transformation of endometriosis: application of laser microdissection for analysis of genetic alterations according to pathological changes [J]. Med Electron Microsc, 2004, 37(2):97-100.
[17] Otsuka J, Okuda T, Sekizawa A, et al. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma [J]. Med Electron Microsc, 2004, 37(3):188-192.
[18] Martini M, Ciccarone M, Garganese G, et al. Possible involvement of hMLH1, p16(INK4a)and PTEN in the malignant transformation of endometriosis [J]. Int J Cancer, 2002, 102(4):398-406.
[19] Obata K, Hoshiai H. Common genetic changes between endometriosis and ovarian cancer [J]. Gynecol Obstet Invest, 2000, 50(Suppl 1):39-43.
[20] Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary[J]. Cancer Res, 2000, 60(24): 7052-7056.
[21] Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas [J]. N Engl J Med, 2010, 363(16):1532-1543.
[22] Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma[J]. Science, 2010, 330(6001):228-231.
[23] Ishikawa M, Nakayama K, Nakamura K, et al. Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients[J]. Oncotarget, 2018, 9(19): 14754-14763.
[24] Akahane T, Sekizawa A, Purwosunu Y,et al. The role of p53 mutation in the carcinomas arising from endometriosis [J]. Int J Gynecol Pathol, 2007, 26(3):345-351.
[25] Bayramoglu H, Duzcan E. Atypical epithelial changes and mutant p53 gene expression in ovarian endometriosis [J]. Pathol Oncol Res, 2001, 7(1):33-38.
[26] Senthong A, Kitkumthorn N, Rattanatanyong P, et al. Differences in LINE-1 methylation between endometriotic ovarian cyst and endometriosis-associated ovarian cancer [J]. Int J Gynecol Cancer, 2014, 24(1):36-42.
[27] Guo C, Ren F, Wang D, et al. RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis [J]. Oncology Rep, 2014, 32(6): 2580-2588.
[28] Perez-Janices N, Blanco-Luquin I, Torrea N, et al. Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis [J]. Oncotarget, 2015, 6(27): 23944-23958.
[29] Suryawanshi S, Vlad AM, Lin HM, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer [J]. Clin Cancer Res, 2013, 19(5): 1213-1224.
[30] Wyman SK, Parkin RK, Mitchell PS, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries [J]. PLoS One, 2009,4(4):e5311. doi: 10.1371/journal.pone.0005311.
[31] Teague EM, Print CG, Hull ML. The role of microRNAs in endometriosis and associated reproductive conditions [J]. Hum Reprod Update, 2010, 16(2):142-165.
[32] Tian X, Xu L, Wang P. MiR-191 inhibits TNF-alpha induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1 [J]. Int J Clin Exp Pathol, 2015,8(5):4933-4942.
[33] Panda H, Pelakh L, Chuang TD, et al. Endometrial miR-200c is altered during transformation into cancerous states and targets the expression of ZEBs, VEGFA, FLT1, IKKbeta, KLF9, and FBLN5 [J]. Reprod Sci, 2012, 19(8):786-796.
[34] Iwabuchi T, Yoshimoto C, Shigetomi H, et al. Oxidative stress and antioxidant defense in endometriosis and its malignant transformation[J]. Oxid Med Cell Longev, 2015, 2015:848595. doi: 10.1155/2015/848595.
[35] Jeney V, Eaton JW, Balla G, et al. Natural history of the bruise: formation, elimination, and biological effects of oxidized hemoglobin[J]. Oxid Med Cell Longev, 2013, 2013:703571. doi: 10.1155/2013/703571.
[36] Chobot V, Hadacek F. Iron and its complexation by phenolic cellular metabolites: from oxidative stress to chemical weapons [J]. Plant Signal Behav, 2010, 5(1):4-8.
[37] Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects [J]. Antioxid Redox Signal, 2013,18(17):2352-2363.
[38] Hevir N, Ribic-Pucelj M, Lanisnik Rizner T. Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: a source of excessive hydroxy-estrogens and ROS? [J]. Mol Cell Endocrinol, 2013, 367(1-2):74-84
[39] Kobayashi H. Potential scenarios leading to ovarian cancer arising from endometriosis [J]. Redox Rep, 2016,21(3):119-126.
[40] Melin AS, Lundholm C, Malki N, et al. Hormonal and surgical treatments for endometriosis and risk of epithelial ovarian cancer [J]. Acta Obstet Gynecol Scand, 2013, 92(5):546-554.
[41] Pearce CL, Stram DO, Ness RB, et al. Population distribution of lifetime risk of ovarian cancer in the United States [J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(4):671-676.

相关文章 15

[1]	张舒淇,江延姣,印丹. 生殖道微生物与子宫内膜异位症发展之间的联系[J]. 山东大学学报 (医学版), 2025, 63(5): 120-126.
[2]	徐萍,张信美. 子宫内膜异位症疼痛的机制[J]. 山东大学学报 (医学版), 2025, 63(10): 1-7.
[3]	黄艳,周应芳,彭超. 青少年子宫内膜异位症的管理要点和策略[J]. 山东大学学报 (医学版), 2025, 63(10): 8-12.
[4]	薛铭,梁静,凌斌. 各种类型子宫内膜异位症疼痛特点及治疗研究进展[J]. 山东大学学报 (医学版), 2025, 63(10): 13-19.
[5]	赵书睿,赵烨. 围绝经期及绝经后期子宫内膜异位症的诊疗现状[J]. 山东大学学报 (医学版), 2025, 63(10): 20-26.
[6]	梁炎春,严莹,麦华希,姚书忠. 地诺孕素在子宫内膜异位症相关性疼痛中的治疗作用:从基础到临床[J]. 山东大学学报 (医学版), 2025, 63(10): 27-33.
[7]	董向毅,刘昕,刘欣欣,徐亚瑄,赵琳丽,陶国伟. 盆腔深部子宫内膜异位症的超声评价[J]. 山东大学学报 (医学版), 2025, 63(10): 34-42.
[8]	刘振花,连雅囡,米国琳. 子宫内膜异位症疼痛的心理因素及干预措施的研究进展[J]. 山东大学学报 (医学版), 2025, 63(10): 43-51.
[9]	杜煜晗,孙莹,杜惠兰. 红花如意丸对寒凝血瘀型子宫内膜异位症痛经患者疼痛的疗效及机制[J]. 山东大学学报 (医学版), 2025, 63(10): 52-60.
[10]	袁宗怀,潘广晔,迟曰梅,安传国,张永刚. 孟德尔随机化分析低级别浆液性卵巢癌与乳腺癌的因果关系[J]. 山东大学学报 (医学版), 2025, 63(1): 99-107.
[11]	何静,严如根,武志红,李长忠. 消癥抑癌方对卵巢癌SKOV3细胞增殖、迁移的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 1-10.
[12]	焦光丽,石子馨,陈蓉,宋亚博,杨飞,崔书君. 基于增强CT影像组学预测卵巢癌患者铂类药物敏感性[J]. 山东大学学报 (医学版), 2023, 61(12): 62-69.
[13]	张丽霞,田一正,吕尚格,张亚男,颜磊. GnRH-a预处理对子宫内膜异位症患者替代方案冻胚移植结局的影响[J]. 山东大学学报 (医学版), 2023, 61(10): 63-68.
[14]	颜磊,岳彩欣,刘懿淳. 子宫内膜异位症的生育力保护[J]. 山东大学学报 (医学版), 2022, 60(9): 31-34.
[15]	冷金花, 史精华. 子宫腺肌病的临床表现[J]. 山东大学学报 (医学版), 2022, 60(7): 1-5.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed